Sanjivani Paranteral Ltd Stock Falls to 52-Week Low of Rs.169

Recent Price Movement and Market Context

The stock opened sharply lower today, down 4.47% from the previous close, and despite an intraday high of Rs.182.95, it ultimately settled at the day’s low of Rs.169. This represents a 1.05% decline on the day and a notable underperformance relative to the Pharmaceuticals & Biotechnology sector, which outperformed by 0.68%. Sanjivani Paranteral Ltd has now recorded losses for three consecutive sessions, resulting in a cumulative decline of 10.37% over this period.

Trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – the stock’s technical indicators signal sustained downward momentum. This contrasts with the broader market, where the Sensex also faced pressure, falling 271.41 points (-0.8%) to 81,523.24 after a negative opening. The Sensex has been on a three-week losing streak, down 4.94%, and is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, indicating mixed medium-term signals.

Financial Performance Highlights

The company’s latest quarterly results have contributed to the subdued sentiment. Net sales for the quarter stood at Rs.15.50 crores, the lowest recorded in recent periods. Profit before depreciation, interest, and taxes (PBDIT) also declined to Rs.2.25 crores, while profit before tax excluding other income (PBT less OI) was Rs.2.03 crores, marking the lowest quarterly figures reported.

Despite these declines in sales and earnings, the company’s return on capital employed (ROCE) remains relatively high at 22.3%. However, this is accompanied by a valuation that appears expensive, with an enterprise value to capital employed ratio of 5.3 times. The stock trades at a premium compared to its peers’ historical averages, which may be a factor in the current market assessment.

Long-Term Performance and Valuation Metrics

Over the past year, Sanjivani Paranteral Ltd’s stock price has declined by 50.04%, a stark contrast to the Sensex’s positive return of 7.50% over the same period. This underperformance is further highlighted when compared to the BSE500 index, which generated a 5.70% return in the last year. The stock’s 52-week high was Rs.363, underscoring the extent of the recent decline.

Profit growth over the past year has been modest, with a 7.8% increase, yet the price-to-earnings-to-growth (PEG) ratio stands at a high 11.5, indicating that the stock’s valuation is not well supported by earnings growth. This disparity between valuation and earnings performance has likely contributed to the recent downgrade in the company’s Mojo Grade from Hold to Sell as of 23 Jul 2025, with a current Mojo Score of 37.0.

Operational and Financial Strengths

Despite the recent price weakness, the company maintains several positive financial attributes. Its return on equity (ROE) is notably high at 187.44%, reflecting strong management efficiency in generating shareholder returns. Additionally, the company’s average debt-to-equity ratio remains low at 0.21 times, indicating a conservative capital structure with limited leverage risk.

Operating profit has demonstrated healthy long-term growth, expanding at an annual rate of 61.92%. This suggests that while recent quarterly results have been subdued, the company has delivered robust profitability growth over a longer horizon.

Shareholding and Market Capitalisation

The majority of Sanjivani Paranteral Ltd’s shares are held by non-institutional investors, which may influence trading patterns and liquidity. The company’s market capitalisation grade is rated at 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.

Given the current market cap and valuation metrics, the stock’s recent price action reflects a combination of sector headwinds, valuation concerns, and recent financial results.

Summary of Key Metrics

To summarise, the stock’s key data points as of 21 Jan 2026 include:

• New 52-week low price: Rs.169


• Three-day consecutive decline: -10.37% total return


• Quarterly net sales: Rs.15.50 crores (lowest recent level)


• Quarterly PBDIT: Rs.2.25 crores


• Quarterly PBT less other income: Rs.2.03 crores


• ROCE: 22.3%


• ROE: 187.44%


• Debt-to-equity ratio: 0.21 times


• PEG ratio: 11.5


• Mojo Score: 37.0 (Sell rating)

These figures illustrate the complex interplay between valuation, profitability, and market sentiment that has culminated in the stock’s recent 52-week low.

Unlock special upgrade rates for a limited period. Start Saving Now →